Skip to main content

Roivant Sciences Ltd.'s Form 4 filing

Immunovant, Inc. (IMVT) · filed Oct 4, 2023

Accession no.
0001140361-23-046976
Filed
Oct 4, 2023
Trade date
Oct 2, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market purchases total $58.0M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Roivant Sciences Ltd.CIK 0001635088Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 2, 2023Common Stock, $0.0001 par value per shareAGrant or awardAcquired+4,473,684$38.00+$169,999,99278,279,015Direct
Oct 2, 2023Common Stock, $0.0001 par value per sharePPurchaseAcquired+1,526,316$38.00+$58,000,00879,805,331Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

The Reporting Person is deemed to be a "director by deputization" of the Issuer for purposes of Section 16 of the Securities Exchange Act of 1934 by virtue of the fact that Frank M. Torti, M.D. (who serves as Vant Chair of Roivant Sciences, Inc. ("RSI"), a subsidiary of the Reporting Person), Eric Venker, M.D., Pharm.D. (who serves as President, Chief Operating Officer of RSI) and Andrew Fromkin (who serves as the Vant Portfolio Operating Partner for RSI) each currently serve on the board of directors of the Issuer on behalf of the Reporting Person.

Read the full filing on SEC EDGAR (opens in a new tab)